Evaluation of Selected MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their Potential Link to Cognition, Depression, and Disability
- 284 Downloads
Accumulating data suggests that miRNAs might play a major role in neuroinflammatory processes. Therefore, our study aimed to first estimate the levels of miR-155, miR-326, and miR-301a in serum of RR-MS patients in the remission phase and then compare the levels of the examined miRNAs at different times after relapse. In this study, 36 RR-MS patients in the remission phase took part. We analyzed two subgroups of RR-MS: one, 1 to 2 months after completing steroid treatment during relapse (post-acute; n = 13) and the other, over 2 years without any relapse (stable; n = 23). Moreover, we made correlations between these biochemical results and clinical parameters of cognitive impairment, depression, and disability. The obtained results presented downregulation of miR-155 and miR-301a (in 94% and 51% samples, respectively) and overexpression of miR-326 (in 72% samples) in RR-MS patients. Moreover, we observed a positive correlation between the relative expression of miRNAs and BDI (Beck Depression Index) for miR-326 (rho = 0.385459, p = 0.022210; Spearman’s rank correlation) and miR-301a (rho = 0.435131, p = 0.008991; Spearman rank correlation). We also observed the differences in expression levels between the post-acute and stable phases of RR-MS. The expression levels of miR-301a and miR155 were higher in the post-acute vs. stable phase of remission (2.385 vs. 0.524 and 0.594 vs. 0.147; respectively). Our study, for the first time, presents miRNA expression differences in two stages of remission: post-acute and stable.
KeywordsMultiple sclerosis Remission miRNA Depression Disability Cognition
We thank all subjects for participating in this study and all of our colleagues in the Neurorehabilitation Ward in the III General Hospital of Lodz, Poland.
This study was supported by research grant for Young scientists from Medical University of Lodz, Poland, nr. 502-03/5-127-05/502-54-174. It had not been published before. This article is the basis of author’s doctoral thesis.
Compliance with Ethical Standards
Conflict of Interest
The authors declare no that they have no conflict of interest.
- Aschrafi A, Verheijen JM, Gordebeke PM, Olde Loohuis NF, Menting K, Jager A, Palkovits M, Geenen B, Kos A, Martens GJ, Glennon JC, Kaplan BB, Gaszner B, Kozicz T (2016) MicroRNA-326 acts as a molecular switch in the regulation of midbrain urocortin 1 expression. J Psychiatry Neurosci 41(5):342–353CrossRefPubMedPubMedCentralGoogle Scholar
- Baulina NM, Kulakova OG, Favorova OO (2016) MicroRNAs: the role in autoimmune inflammation. Acta Nat 8(1):21–33Google Scholar
- Bendszus M, Storch-Hagenlocher B (2013) Multiple sclerosis and other demyelinating diseases. In: Hähnel S (ed) Inflammatory diseases of the brain. Springer, Berlin, Heidelberg p. 3–18Google Scholar
- Faria O, Moore CS, Kennedy TE, Antel JP, Bar-Or A, Dhaunchak AS (2012) MicroRNA dysregulation in multiple sclerosis. Front Genet 3:311Google Scholar
- Fenoglio C, Cantoni C, de Riz M, Ridolfi E, Cortini F, Serpente M, Villa C, Comi C, Monaco F, Mellesi L, Valzelli S, Bresolin N, Galimberti D, Scarpini E (2011) Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett 504:9–12CrossRefPubMedGoogle Scholar
- Freiesleben S, Hecker M, Zettl UK, Fuellen G, Taher L (2016) Analysis of microRNA and gene expression profiles in multiple sclerosis: integrating interaction data to uncover regulatory mechanisms. Sci Rep 6. https://doi.org/10.1038/srep34512
- Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 4:423–433Google Scholar
- Wang K, Zhang S, Weber J, Baxter D, Galas DJ (2010) Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 38(20):7248–7259Google Scholar
- Wu T, Chen G (2016) miRNAs participate in MS pathological processes and its therapeutic response. Mediat Inflamm. https://doi.org/10.1155/2016/4578230